Oncotarget Contribution to Cancer Research

Since 2010, Oncotarget has been covering research in the field of oncology. It also publishes other sections on topics outside oncology. Oncotarget has open access to its peer-reviewed research, and it is published in Impact Journals. The present editor in chief is Mikhail Blagosklonny and Andrei V. Gudkov. Oncotarget may not offer direct treatment to patients, but increasing knowledge is an essential role. Medical professionals and the general population need limitless information about cancer. People should know types, causes, management and treatment among other things.

Cancer diseases are numerous and have claimed many lives over the years. For this reason, Oncotarget is contributing by spreading news of any research that provides solutions to cancer. Much progress has been made in oncology, and cancer treatments are increasing. In every week, Oncotarget publishes twice for its audiences. Anyone can access these journals and utilize them. Professionals in the medical field have benefited greatly from applying the knowledge they acquired from Oncotarget. Visit Soundcloud to listen an audio podcast of Oncotarget.

Recently, Oncotarget published new research indicating a breakthrough in treating breast cancer. It does not matter how aggressive breast cancer cells could get, they can respond to hormone therapy. However, these cells ought to express a particular protein called estrogen receptor beta. Researchers continue to work on this finding by including the development of drugs. By knowing the type of cancers and how they respond to treatment, researchers will work around the existing gaps.

Learn more: https://www.ncbi.nlm.nih.gov/pmc/journals/1558/

This study points out that efficient treatment breast cancer requires a detailed understanding of every type. For example, some breast cancer cells will express estrogen receptor alpha while others have estrogen receptor beta. A small number of patients are diagnosed with Triple negative breast cancer. This type does not have any protein receptor. Researchers will continue to uncover new information on how to address the loopholes.

Oncotarget is the biggest publication of peer-reviewed research on oncology. Last year, it awarded four biomedical researchers a travel grant to Singapore. They attended Frontiers in Cancer Science 2017. It is a conference that facilitates discussions on the discoveries of cancer. This participation aims to increase circulation of research. Oncotarget is committed to spreading information on findings in research. Visit Oncotarget’s profile page at facebook.com